Karin Meiser

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

Philip J. Mease, Désirée van der Heijde, Robert Landewé et al. · Annals of the Rheumatic Diseases · 2018 · 284 citations · Full text

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses

Gail M. Gauvreau, P. Jonathan, Louis‐Philippe Boulet et al. · Journal of Allergy and Clinical Immunology · 2016 · 135 citations · Full text

Asthma, Versus Omalizumab, Allergy +8

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

Ildikó Madurka, Alexander Vishnevsky, Joan B. Soriano et al. · Infection · 2022 · 77 citations · Full text

New Oral Nlrp3, Early Phase 2A, Antiviral Therapy +4

Pharmacodynamic Effects of Steady‐State Fingolimod on Antibody Response in Healthy Volunteers: A 4‐Week, Randomized, Placebo‐Controlled, Parallel‐Group, Multiple‐Dose Study

Craig Boulton, Karin Meiser, Olivier David et al. · The Journal of Clinical Pharmacology · 2011 · 66 citations

A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia

David C. Rees, Selma Ünal, Carlton Dampier et al. · Blood · 2022 · 37 citations · Full text